The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective

Stephen G. Post, Peter J. Whitehouse, Robert H. Binstock, Thomas D. Bird, Sharen K. Eckert, Lindsay A. Farrer, Leonard M. Fleck, Atwood D. Gaines, Eric T. Juengst, Harry Karlinsky, Steven Miles, Thomas H. Murray, Kimberly A. Quaid, Norman R. Relkin, Allen D. Roses, P. H. St. George-Hyslop, Greg Sachs, Bonnie Steinbock, Edward F. Truschke, Arthur B. Zinn

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Objective.-Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia. This statement addresses arguments for and against clinical genetic testing. Participants.-The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z., and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995- 1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. Evidence.-All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. Consensus Process.-The first draft was written in April 1996 by the principal investigator (S .G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. Conclusions.-Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.

Original languageEnglish
Pages (from-to)832-836
Number of pages5
JournalJournal of the American Medical Association
Volume277
Issue number10
StatePublished - Mar 12 1997
Externally publishedYes

Fingerprint

Genetic Testing
Consensus
Alzheimer Disease
Research Personnel
Focus Groups
National Human Genome Research Institute (U.S.)
Dementia
Chromosomes, Human, Pair 4
Inborn Genetic Diseases
Group Processes
Disease Susceptibility
Genetic Counseling
National Institutes of Health (U.S.)
Public Policy
Ethics
Caregivers
Volunteers
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Post, S. G., Whitehouse, P. J., Binstock, R. H., Bird, T. D., Eckert, S. K., Farrer, L. A., ... Zinn, A. B. (1997). The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective. Journal of the American Medical Association, 277(10), 832-836.

The clinical introduction of genetic testing for Alzheimer disease : An ethical perspective. / Post, Stephen G.; Whitehouse, Peter J.; Binstock, Robert H.; Bird, Thomas D.; Eckert, Sharen K.; Farrer, Lindsay A.; Fleck, Leonard M.; Gaines, Atwood D.; Juengst, Eric T.; Karlinsky, Harry; Miles, Steven; Murray, Thomas H.; Quaid, Kimberly A.; Relkin, Norman R.; Roses, Allen D.; St. George-Hyslop, P. H.; Sachs, Greg; Steinbock, Bonnie; Truschke, Edward F.; Zinn, Arthur B.

In: Journal of the American Medical Association, Vol. 277, No. 10, 12.03.1997, p. 832-836.

Research output: Contribution to journalArticle

Post, SG, Whitehouse, PJ, Binstock, RH, Bird, TD, Eckert, SK, Farrer, LA, Fleck, LM, Gaines, AD, Juengst, ET, Karlinsky, H, Miles, S, Murray, TH, Quaid, KA, Relkin, NR, Roses, AD, St. George-Hyslop, PH, Sachs, G, Steinbock, B, Truschke, EF & Zinn, AB 1997, 'The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective', Journal of the American Medical Association, vol. 277, no. 10, pp. 832-836.
Post SG, Whitehouse PJ, Binstock RH, Bird TD, Eckert SK, Farrer LA et al. The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective. Journal of the American Medical Association. 1997 Mar 12;277(10):832-836.
Post, Stephen G. ; Whitehouse, Peter J. ; Binstock, Robert H. ; Bird, Thomas D. ; Eckert, Sharen K. ; Farrer, Lindsay A. ; Fleck, Leonard M. ; Gaines, Atwood D. ; Juengst, Eric T. ; Karlinsky, Harry ; Miles, Steven ; Murray, Thomas H. ; Quaid, Kimberly A. ; Relkin, Norman R. ; Roses, Allen D. ; St. George-Hyslop, P. H. ; Sachs, Greg ; Steinbock, Bonnie ; Truschke, Edward F. ; Zinn, Arthur B. / The clinical introduction of genetic testing for Alzheimer disease : An ethical perspective. In: Journal of the American Medical Association. 1997 ; Vol. 277, No. 10. pp. 832-836.
@article{13c5650062bb4510a37f1f6a8f8fa8c9,
title = "The clinical introduction of genetic testing for Alzheimer disease: An ethical perspective",
abstract = "Objective.-Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia. This statement addresses arguments for and against clinical genetic testing. Participants.-The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z., and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995- 1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. Evidence.-All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. Consensus Process.-The first draft was written in April 1996 by the principal investigator (S .G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. Conclusions.-Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.",
author = "Post, {Stephen G.} and Whitehouse, {Peter J.} and Binstock, {Robert H.} and Bird, {Thomas D.} and Eckert, {Sharen K.} and Farrer, {Lindsay A.} and Fleck, {Leonard M.} and Gaines, {Atwood D.} and Juengst, {Eric T.} and Harry Karlinsky and Steven Miles and Murray, {Thomas H.} and Quaid, {Kimberly A.} and Relkin, {Norman R.} and Roses, {Allen D.} and {St. George-Hyslop}, {P. H.} and Greg Sachs and Bonnie Steinbock and Truschke, {Edward F.} and Zinn, {Arthur B.}",
year = "1997",
month = "3",
day = "12",
language = "English",
volume = "277",
pages = "832--836",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - The clinical introduction of genetic testing for Alzheimer disease

T2 - An ethical perspective

AU - Post, Stephen G.

AU - Whitehouse, Peter J.

AU - Binstock, Robert H.

AU - Bird, Thomas D.

AU - Eckert, Sharen K.

AU - Farrer, Lindsay A.

AU - Fleck, Leonard M.

AU - Gaines, Atwood D.

AU - Juengst, Eric T.

AU - Karlinsky, Harry

AU - Miles, Steven

AU - Murray, Thomas H.

AU - Quaid, Kimberly A.

AU - Relkin, Norman R.

AU - Roses, Allen D.

AU - St. George-Hyslop, P. H.

AU - Sachs, Greg

AU - Steinbock, Bonnie

AU - Truschke, Edward F.

AU - Zinn, Arthur B.

PY - 1997/3/12

Y1 - 1997/3/12

N2 - Objective.-Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia. This statement addresses arguments for and against clinical genetic testing. Participants.-The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z., and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995- 1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. Evidence.-All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. Consensus Process.-The first draft was written in April 1996 by the principal investigator (S .G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. Conclusions.-Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.

AB - Objective.-Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia. This statement addresses arguments for and against clinical genetic testing. Participants.-The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z., and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995- 1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. Evidence.-All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. Consensus Process.-The first draft was written in April 1996 by the principal investigator (S .G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. Conclusions.-Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.

UR - http://www.scopus.com/inward/record.url?scp=0001547777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0001547777&partnerID=8YFLogxK

M3 - Article

C2 - 9052715

AN - SCOPUS:0001547777

VL - 277

SP - 832

EP - 836

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 10

ER -